McCarter & English, LLP
Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereof
The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1) gene, the Factor XII (Hageman Factor (F12) gene, or the Kininogen 1 (KNG1) gene, and methods of using such RNAi agents to inhibit expression of a KLKB1 gene, an F12 gene, and/or a KNG1 gene, and methods of treating subjects having an hereditary angioedema (HAE) and/or a contact activation pathway-associated disorder.
Alny lam Pharmaceuticals, Inc.
C C A A C C A C C C A A A C A A
C12N C12N A61K A61P C12N C12N A61K C12N C12N C12Q A61P A61K A61P C12N A61P A61P
inventional additional inventional inventional additional inventional inventional additional additional inventional inventional inventional inventional additional inventional inventional
Martin A. Gregory Akin Jingxuan James
Maier Hinkle Akinc Liu Butler